





### **CNMI Weekly Syndromic Surveillance Report**

**EPI WEEK 14 EPI WEEK DATE:** March 30, 2025 – April 05, 2025

Clinic	Influenza-Like-Illness (ILI)		Diarrhea (DIA)		Prolonged Fever (PF)		Acute Fever and Rash (AFR)		Total Encounters	
	Last week	Current week	Last week	Current week	Last week	Current week	Last week	Current week	Last week	Current week
CHCC Family Care Clinic	2	0	1	0	0	1	0	0	322	407
CHCC Women's Clinic	0	0	0	0	0	0	0	0	112	140
CHCC Children's Clinic	4	9	0	2	5	8	0	0	154	223
CHCC Emergency Room	19	13	6	10	8	14	0	0	400	423
Kagman Isla Community Health	0	0	1	0	0	0	0	0	108	109
Tinian Isla Community Health	0	0	0	0	0	0	0	0	33	67
Southern Isla Community Health	0	2	0	0	0	0	0	0	136	98
CHCC Tinian Health Center	4	1	0	1	2	3	0	0	111	112
CHCC Rota Health Center	1	2	0	0	2	0	0	0	109	111
	30	27	8	13	17	26	0	0	1485	1690

#### **ALERTS AND TRENDS**

**ILI: Decrease** from previous week

**DIA: Increase** from previous week

**PF**: **Increase** from previous week

AFR: Stable from previous week

#### **KEY TAKEAWAYS**

- > 14% Increase in Total Encounters from the last Epi Week to the current Epi Week.
- ➤ 13% Decrease in Influenza Like Illness cases were seen this Epi Week (#14) compared to the average of the previous 3 Epi Weeks (#13, 12, & 11).
- ➤ 86% Increase in Prolonged Fever cases were seen this Epi Week (#14) compared to the average of the previous 3 Epi Weeks (#13, 12, & 11).
  - **❖** 5 Influenza cases:
  - ❖ 4 Flu A & 1 Flu B

Epi Week				Percent (%) change from	Antimicrobial Resistant (AMR) Infections				
Syndromes	14	13	12	11	current week to previous 3 weeks	Organism	EW 14	2025 YTD Totals	
Influenza-Like Illness	27	30	23	40	-13%	MRSA	2	19	
Diarrhea	13	8	9	8	56%	VRE	0	2	
Prolonged Fever	26	17	10	15	86%	ESBL	5	38	
Acute Fever and Rash	0	0	0	0	0%	CRE	0	0	







Commonwealth of the Northern Mariana Islands

### **CNMI Weekly Syndromic Surveillance Trends**

**EPI WEEK 14 EPI WEEK DATE:** March 30, 2025 – April 05, 2025











Commonwealth of the Northern Mariana Islands

### **CNMI Weekly Syndromic Surveillance Trends**

**EPI WEEK DATE:** March 30, 2025 – April 05, 2025









Commonwealth of the Northern Mariana Islands

### **CNMI Weekly Notifiable Disease Report for Select NNDs**

**EPI WEEK DATE:** March 30, 2025 – April 05, 2025

In the table below, weekly and year to date counts are displayed for Epi Week 14 and 2025, respectively. Additionally, a 3-year weekly average is calculated for the same Epi Week from the previous 3 years (2022-2024) for comparison to the current week. Incidence rates are calculated for 2024 and 2025 using the estimated population for the CNMI from the U.S. Census Bureau.

Condition	Epi Week 14	2025 YTD	3-year weekly average counts	2025 YTD Incidence Rates*	2024 Incidence Rates*
Enteric Diseases:					
Campylobacter	1	2	0	3.9	35.2
Ciguatera fish poisoning	0	2	0	3.9	9.8
Salmonella	0	4	0	7.9	43.0
Environmental:					
Elevated Blood Lead Levels	0	0	0	0.0	7.8
Sexually Transmitted Infections:					
Chlamydia	8	72	4	141.3	418.6
Gonorrhea	0	8	0	15.7	48.9
Syphilis	0	1	0	2.0	5.9
Respiratory Infections:					
Influenza	5	247	-	484.8	831.4
RSV	0	3	-	5.9	142.8
COVID-19	3	30	28	58.9	1299.0
Tuberculosis:					
TB, Confirmed	0	2	0	3.9	19.6
TB, Under Investigation	0	5	0	9.8	7.8

<sup>\*</sup>Rate per 100,000; Data are preliminary and subject to change. CNMI population estimates were determined using 2024 and 2025 Census International Database (<a href="https://www.census.gov/data-tools/demo/idb/#/country?YR">https://www.census.gov/data-tools/demo/idb/#/country?YR</a> ANIM=2021&COUNTRY YR ANIM=2021&FIPS SINGLE=CQ)







#### **CNMI Weekly Prescription Drug Monitoring Program (PDMP) Report**

EPI WEEK 14 EPI WEEK DATE: MARCH 30 - APRIL 5, 2025

WEEKLY CASE COUNTS											
POLYSUBSTANCE OPIOID				STIMULANT		BENZODIAZEPINE			OTHER SUBSTANCE		
OVERDOSE	MISUSE	OVERDOSE	OUD	MISUSE	OVERDOSE	StUD	MISUSE	OVERDOSE	BUD	MISUSE	OVERDOSE
0	3	0	0	0	0	0	5	0	0	2	1


NOTE: The encounters have been monitored since 2020. Some individuals might be involved in multiple cases or flagged multiple times for the same type of encounter in a single EPI week. The overdose Surveillance has expanded to include Stimulant and Polysubstance cases in 2021, Benzodiazepine cases in 2022. The Polysubstance cases are also counted under respective categories. Prior cases of any overdose related encounters might be duplicated under Other Substance Overdose category. Other Substance category analysis is solely depending on indications from the providers' notes. The substances reported are not verified by NDC number or DEA substance database.



PDMP data to support the patients' statement.



- NON-FATAL OVERDOSE
- SUBSTANCE USE DISORDER or MISUSE



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52

**EPI WEEK #** 

	CASE: DEFINITION		
OVERDOSE	Injury to the body (poisoning) that happens when a drug is taken in excessive amounts. An overdose can be fatal or nonfatal, accidental or intentional.		
POLY-SUBSTANCE	The use of more than one drug, also known as polysubstance use, is common. This includes when two or more are taken together or within a short time period, either intentionally or unintentionally. Intentional polysubstance use occurs when a person takes a drug to increase or decrease the effects of a different drug or wants to experience the effects of the combination. Unintentional polysubstance use occurs when a person takes drugs that have been mixed or cut with other substances, like fentanyl, without their knowledge. Whether intentional or not, mixing drugs is never safe because the effects from combining drugs may be stronger and more unpredictable than one drug alone, and even deadly.  *For overdose Surveillance, Poly-Substance Use only includes encounters associated with Opioids, Stimulants, and/or Benzodiazepines.		
MISUSE	The use of illegal drugs and/or the use of prescription drugs in a manner other than as directed by a doctor, such as use in greater amounts, more often, or longer than told to take a drug or using someone else's prescription.		
OPIOID USE DISORDER	A problematic pattern of opioid, stimulant, or benzodiazepine uses that lead to serious impairment or distress. Diagnosing OUD/SUD/BUD requires a		
STIMULANT USE DISORDER	thorough evaluation, which may include obtaining the results of urine drug testing and prescription drug monitoring program (PDMP) reports, when		
BENZODIAZEPINE USE DISORDER  OUD/SUD/BUD is suspected. A diagnosis is based on specific criteria such as unsuccessful efforts to cut down or control use, or use resulting problems and a failure to fulfill obligations at work, school, or home, among other criteria.			
SUSPECTED MISUSE	Any encounters that possibly leading to the above descriptions with such providers' comments as "requesting prescription refills (at emergency department)", "drug-seeking-behavior", and "frequent ER visitor for the same complaint for chronic pain and requesting 'stronger' medication". Also, cases where providers indicate there is possibility for misuse on the EHR system or when patients inform that they took Oxycodone (for example) and no		

#### SENTINEL SITES

#### Commonwealth Healthcare Corporation (CHCC)

ER - Emergency Room, PCAP - Primary Care Access Point, CC - Children's Clinic, FCC - Family Care Clinic, WC - Women's Clinic,

THC - Tinian Health Clinic, RHC - Rota Health Center

Private Clinic

KICH - Kagman Isla Community Health,

TICH - Tinian Isla Community Health,

SICH - Southern Isla Community Health







### **CNMI Weekly Health & Vital Statistics Report**

#### **REPORTING PERIOD: EPI YEAR 2025 as of EPI WEEK 14**

The statistics on births, deaths, and causes of deaths in this report are derived from birth and death registrations processed daily at the Health and Vital Statistics Office.

Num     Aver	ber of births: age:	9 <u>(138)</u> 10(per week)		•	Numbe Averag	er of death ge:	s:	<b>7</b> <u>(6</u> 4 <u>(</u> p	5 <u>3)</u> oer week)		
• Infec	tions present an	d/or treated durir	ng	•	Numbe	er of death	s who re	ceived C	OVID-19 vaco	ine:	
preg	nancy:										
0	Chlamydia:		<b>0</b> (2)		Age ra	nge:	< 5	≥ 5	12-17	18 & over	
0	Gonorrhea:		<b>O</b> (0)		N∘ of	death	<b>0</b> (2)	<b>O</b> (0)	<b>O</b> (O)	7(61)	
0	Syphilis:		<b>O</b> (0)		N∘ Va	accinated	<b>O</b> (0)	<b>0</b> (0)	<b>O</b> (0)	6(46)	
0	Hepatitis B:		<b>O</b> (1)		% Va	ccinated	0%	0%	0%	75%	
0	Hepatitis C:		<b>O</b> (0)								
0	COVID-19:		<b>O</b> (0)	•	<u>Mortal</u>	ity Surveill	ance:			7	<u>(63)</u>
• Subs	tance use during	pregnancy:	. ,		o Non-c	ommunical	ble disea	ses:		6	5(51)
	្ស Digarette smoking		<b>0</b> (2)		•	Cancer rel	ated dea	ths		0	(12)
O E	0(40)				<ul> <li>Tobacco related deaths</li> </ul>						<b>O</b> (7)
o E	2/44)				o COVID-19 related deaths:						<b>O</b> (0)
0 A	o Alcohol use: <b>0</b> (1)				<ul> <li>COVID-19 other contributing conditions<sup>1</sup></li> </ul>						<b>O</b> (0)
0 [	Orug use: (Cannal	bis, Crystal meth-	<b>0</b> (2)		-	COVID-19	טנוופו נט	ntributin	y conditions		<b>U</b> (0)
	Ice, Op	ioid, Others, etc.)			o Fetal I	Deaths²:					<b>O</b> (2)
0 E	E-Cigarette use:		<b>0</b> (2)								
	■ 3 months be	efore pregnancy	<b>O</b> (0)		o Infant	Deaths:					<b>0</b> (2)
	<ul><li>During preg</li></ul>	nancy	<b>0</b> (2)			en (aged 1	- 4 vears	) Deaths:	:		<b>0</b> (0)
• Mate	ernal risk factors	in pregnancy:				nal Deaths	-	, = = = = = = = = = = = = = = = = = = =	•		<b>O</b> (0)
0 F	Pre-pregnancy DN	<b>√</b> 1:	<b>O</b> (1)								
0 (	Gestational DM:		<b>1</b> (14)		O Accide	ent or Injur	y Relate	d Deaths	3 <sup>3</sup> :		<b>O</b> (0)
0 F	Pre-pregnancy HT	ΓN:	0(4)		•	Drowning	:				<b>O</b> (0)
0 (	Gestational HTN:		<b>3</b> (10)		•	Suicide:					<b>O</b> (0)
• Infan	t risk factors (Lo	w survival births)			•	Homicide:					<b>O</b> (0)
O E	Birth weight < 150	00 grams:	<b>O</b> (0)		•	Traffic fat	ality:				<b>O</b> (0)
	Birth weight < 250	•	<b>2</b> (11)		•	Drug and/	or opioid	doverdo	se:		0(1)
0 (	Gestation age < 3	7 weeks:	<b>0</b> (11)			Poisoning	•				<b>0</b> (0)

¹ Other significant condition contributing to death but NOT resulting in the underlying cause.² Fetal deaths = Fetus weighed ≥ 350 grams, or fetal demise > 20 weeks of completed gestation.

Data source: Electronic Vital Registration System (EVRS)

<sup>&</sup>lt;sup>3</sup> Accident or Injury related deaths = Manner of death beyond Natural Causes: accidental deaths (traffic and drowning), suicide, drug overdose, and poisoning.








7

### **CNMI Weekly Health & Vital Statistics Report**


#### REPORTING PERIOD: EPI YEAR 2025 as of EPI WEEK 14

The statistics on births, deaths, and causes of deaths in this report are derived from birth and death registrations processed daily at the Health and Vital Statistics Office.



<sup>&</sup>lt;sup>4</sup>Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified; <sup>5</sup> Mental, Behavioral and Neurodevelopmental disorders; <sup>6</sup>Certain conditions originating in the perinatal period; <sup>7</sup>Congenital malformations, deformations and chromosomal abnormalities; <sup>8</sup>Injury, poisoning and certain other consequences of external causes; <sup>9</sup>Diseases of the musculoskeletal system and connective tissue, <sup>10</sup>Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism





(EpiWeek)